Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | ANPEP | P15144 | 2/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | ADH1B | P00325 | 1/20 | 0.37 |
| ▸ | ADH1C | P00326 | 1/20 | 0.37 |
| ▸ | ADH1A | P07327 | 1/20 | 0.37 |
| ▸ | ADH4 | P08319 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7747093 | 1.00 | KDM4E (0.48) | KDM4EALDH1A1HSD17B10SMN1; SMN2ANPEP | |
| SCHEMBL7748472 | 1.00 | KDM4E (0.48) | KDM4EALDH1A1HSD17B10SMN1; SMN2ANPEP | |
| SCHEMBL1051109 | 0.97 | — | — | |
| SCHEMBL7747239 | 0.92 | — | — | |
| SCHEMBL2881872 | 0.87 | — | — | |
| SCHEMBL940071 | 0.78 | EPHX1 (0.38) | KDM4EALDH1A1SMN1; SMN2EPHX1NPC1 | |
| SCHEMBL940070 | 0.78 | EPHX1 (0.38) | KDM4EALDH1A1SMN1; SMN2EPHX1NPC1 | |
| SCHEMBL8491948 | 0.78 | — | — | |
| SCHEMBL7747174 | 0.76 | MEN1 (0.46) | KDM4EALDH1A1EPHX2NPSR1 | |
| SCHEMBL7742434 | 0.76 | MEN1 (0.46) | KDM4EALDH1A1EPHX2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117794923-A | Benzodioxane compound, and preparation method and application thereof | 南京红云生物科技有限公司 | 2024-03-29 | — | — | CN | claimed |
| EP-1608311-B1 | USE OF LOW MOLECULAR WEIGHT THROMBIN INHIBITORS IN CHOLESTEROL-LOWERING THERAPY | ASTRAZENECA AB (SE) | 2010-07-28 | — | — | EP | claimed |
| EP-1078002-B1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LAB (US) | 2008-05-21 | — | — | EP | claimed |
| EP-1461356-A4 | HEXA-, HEPTA-, AND OCTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LAB (US) | 2007-12-12 | — | — | EP | claimed |
| US-20070167376-A1 | Hexa-, Hepta-, and Octapeptides Having Antiangiogenic Activity | HAVIV FORTUNA | 2007-07-19 | — | — | US | claimed |
| US-7122625-B2 | Hexa-, hepta-, and octapeptides having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2006-10-17 | — | — | US | claimed |
| US-20060194737-A1 | Hepta-, octa-and nonapeptides having antiangiogenic activity | HAVIV FORTUNA | 2006-08-31 | — | — | US | claimed |
| US-7067490-B2 | Hepta-, Octa-and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2006-06-27 | — | — | US | claimed |
| US-20050124548-A1 | Peptide antiangiogenic drugs | HENKIN JACK (US) | 2005-06-09 | — | — | US | claimed |
| EP-1401453-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-04-06 | — | — | EP | claimed |
| WO-1994014842-A1 | DIFLUORO-PENTAPEPTIDE DERIVATIVE ANTI-INFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 1994-07-07 | — | — | WO | claimed |
| WO-1993008211-A1 | TRIPEPTIDE DERIVATIVE ANTI-INFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 1993-04-29 | — | — | WO | claimed |
| US-5116974-A | ANTIARRHYTHMIA | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 1992-05-26 | — | — | US | claimed |
| US-4672054-A | Process for the preparation of angiotensin-II analogues substituted in the 1-, 5- and 8- positions | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1987-06-09 | — | — | US | claimed |
| EP-0171270-A2 | Process for the preparation of angiotensin-II analogues substituted in the 1-, 5- and 8-positions | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1986-02-12 | — | — | EP | claimed |
| US-4568636-A | QUANTITATIVE ANALYSIS OF PROTEOLYTIC ENZYMES, FLUORESCENCE; COLORIMETRIC ANALYSIS | PENTAPHARM AG (CH) | 1986-02-04 | — | — | US | claimed |
| US-4428874-A | QUANTITATIVE ANALYSIS OF PROTEOLYTIC ENZYMES | PENTAPHARM A.G. (CH) | 1984-01-31 | — | — | US | claimed |
| EP-0019589-B1 | TRIPEPTIDE DERIVATIVES AND THEIR USE IN A PROCESS FOR DETERMINING ENZYMES | Pentapharm A.G. (CH) | 1983-11-09 | — | — | EP | claimed |
| WO-1980002559-A1 | TRIPEPTIDIC DERIVATIVES | PENTAPHARM AG (CH) | 1980-11-27 | — | — | WO | claimed |
| EP-0019589-A1 | Tripeptide derivatives and their use in a process for determining enzymes | Pentapharm A.G. (CH) | 1980-11-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124548-A1 | Peptide antiangiogenic drugs | VEGFA, NPPA, FLT1 | KDM4E 4413/4885ALDH1A1 1309/4885HSD17B10 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.